Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Agastra Lab
Philadelphia, Pennsylvania, USAagastra.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Agastra is a pre-clinical stage biotechnology company focused on developing next-generation RNA-based therapies for cardiovascular diseases, specifically heart failure. Co-founded by leading researchers from the University of Pennsylvania, including Dr. Thomas Cappola and Dr. Kiran Musunuru, the company leverages mRNA and potentially circular RNA (circRNA) technology to restore cardiac function. Agastra's approach involves the delivery of therapeutic RNA to the heart to express proteins that can repair or improve the performance of failing heart tissue. The company is part of the growing ecosystem of RNA therapeutics startups emerging from academic research in Philadelphia and is supported by PCI Ventures.
- Therapeutic areas
- Cardiovascular
- Modalities
- mRNA-based drugsRNA therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Agastra Lab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Agastra Lab.